Medical Marijuana Research: The Cannabis Consortium Review of the Literature

Sharon Anavi-Goffer, Michael Bloch, Cathy Budman, Barbara Coffey, Keith Coffman, Joohi Jimenez-Shahed, Irene Malaty, Kirsten Muller-Vahl, Paul Sandor, Diana Shineman, John Walkup, Abraham Weizman, International Advisory Consortium on Medical cannabis/related drugs for Tourette and Tic Disorders

Research output: Book/ReportOther Report

Abstract

The Tourette Association of America (TAA) understands and supports the need to improve the treatment of Tourette Syndrome (TS), Tic Disorders, and co-occurring conditions. The TAA has a track record of funding the development, evaluation and dissemination of effective treatments including pharmacological, behavioral and alternative therapies that reduce the burden of TS and Tic Disorders on our community. Based on currently available evidence, we provide here our current summary of the existing literature on the use of medical marijuana (cannabis) and cannabis-based medications for TS:

A reduction in tics with medical marijuana and cannabis-based medicines has been reported in small studies, patient reports and anecdotal case reports. The neurobiological pathways targeted by medical marijuana and related therapies are deserving of more research and larger scale studies.
There is the potential for adverse effects from medical marijuana and related plant-derived extracts that raise concern for treatment, especially in children and adolescents.
The TAA supports removing regulatory barriers to allow for large-scale research studies of medical marijuana. There is currently insufficient scientific evidence to reach a definitive conclusion on the efficacy and safety of medical marijuana, cannabis-based medications, or related plant-derived extracts for the treatment of TS and other Tic Disorders.
Original languageEnglish
PublisherTourette Association of America
Number of pages10
Publication statusPublished - 12 Sept 2019

Bibliographical note

TAA partners with many corporations including pharmaceutical companies. Abide Pharmaceuticals, mentioned in this report, is developing a synthetic monoacylglycerol lipase (MAGL) inhibitor for Tourette Syndrome, is a corporate sponsor of TAA. The TAA does not endorse any medicines or products.

Keywords

  • 888-4-TOURET

Fingerprint

Dive into the research topics of 'Medical Marijuana Research: The Cannabis Consortium Review of the Literature'. Together they form a unique fingerprint.

Cite this